Amarin Corp Plc (AMRN)

[rfj1862]

I noted that the latest presentation confirms "Top line result supported by robust demonstrations of efficacy across multiple secondary endpoints."

Now if this were a big pharma company with a legal team breathing down their neck and clearing everything they say "multiple" would mean at least 3 secondary end points. Which in turn would mean, given hierarchical testing, that at least all of the following would be statistically significant:

Composite of CV death, nonfatal MI, or nonfatal stroke
Composite of CV death or nonfatal MI
Fatal or nonfatal MI

But since Amarin is not a giant pharmaceutical company with a large legal team breathing down their necks, they may be less cautious with their language.